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Objectives: Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease with
complex pathogenesis involving a variety of immunological events. Recently, it has been
suggested that kynurenic acid (KYNA) might be a potential regulator of inflammatory
processes in arthritis. KYNA has a definitive anti-inflammatory and immunosuppressive
function. The aim of the present study is to investigate the complex effects of a newly
synthesized KYNA analog—SZR72 on the in vitro production of tumor necrosis factor-α
(TNF-α), tumor necrosis factor-stimulated gene-6 (TSG-6), calprotectin (SA1008/9),
SA100 12 (EN-RAGE), and HNP1–3 (defensin-α) in the peripheral blood of patients with
RA and the various effects of the disease.
Methods: Patients with RA (n = 93) were selected based on the DAS28 score,
medication, and their rheumatoid factor (RF) status, respectively. Peripheral blood
samples from 93 patients with RA and 50 controls were obtained, and activated by
heat-inactivated S. aureus. Parallel samples were pretreated before the activation with
the KYNA analog N-(2-N, N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide
hydrochloride. Following the incubation period (18 h), the supernatants were tested for
TNF-α, TSG-6, calprotectin, S100A12, and HNP1–3 content by ELISA.
Results: SZR72 inhibited the production of the following inflammatory mediators:
TNF-α, calprotectin, S100A12, and HNP1–3 in whole blood cultures. This effect was
Balog et al. Kynurenic Acid and Rheumatoid Arthritis
observed in each group of patients in various phases of the disease. The basic (control)
levels of these mediators were higher in the blood of patients than in healthy donors. In
contrast, lower TSG-6 levels were detected in patients with RA compared to healthy
controls. In addition, the KYNA analog exerted a stimulatory effect on the TSG-6
production ex vivo in human whole blood cultures of patients with RA in various phases
of the disease.
Conclusion: These data further support the immunomodulatory role of KYNA in RA
resulting in anti-inflammatory effects and draw the attention to the importance of the
synthesis of the KYNA analog, which might have a future therapeutic potential.
Keywords: kynurenine, TNF-α, TSG-6, TNFα-stimulated gene-6, calgranulins, HNP1–3, rheumatoid arthritis
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, inflammatory joint
disease of autoimmune nature. The pathogenesis of the disease is
complex, involving both immunological and genetic factors (1).
RA is a systemic disease, but a variety of immunological events
may occur outside the joint (2). Cytokines are known to have
an established role in the disease pathogenesis. Pro-inflammatory
cytokines, such as tumor necrosis factor-α (TNF-α), IL-1, and
IL-17, provoke and maintain inflammation as well as bone and
cartilage degradation (3). It is plausible and noteworthy that
FIGURE 1 | The structures of (A) kynurenic acid (KYNA) and (B) of the KYNA
analog 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one
hydrochloride (18, 19) SZR72.











Age, years 58 [46–67] 60 [53–67] 67 [59–73] 63 [55–73] 64 [56–74]
Gender, male/female 8/42 5/25 2/16 7/20 6/12
RA duration, years – 16 [4–19] 11 [3–19] 8 [1–12] 1.5b,c [0.33–9]
Rheumatoid factor (U/mL) – 258 [92–500] 84 [19–428] 94 [42–468] 181 [17–500]
Anti-MCV (U/mL) – 309 [53–999] 90 [24–825] 158 [55–−895] 83 [17–491]
CRP (mg/L) BLD [BLD−2.3] BLD [BLD−3.9] 3.6 [BLD−6.5] 11.4a,b,c [7.3–28] 23a,b,c [8.5–66]
ESR (mm/h) 7.5 [5–9] 11.5 [7–22] 25a [12–44] 38a,b [26–58] 38a,b [25–78]
Data are expressed as median [interquartile range]. Comparisons were made using the Kruskal–Wallis test. ap < 0.05 vs. healthy individuals, bp < 0.05 vs. RA remission, cp < 0.05 vs.
RA mild. BLD, below the level of detection (<2 mg/L).
anti-cytokine agents seem to emerge as potent biological active
molecules in the treatment of RA (4, 5).
Recently, it has been suggested that kynurenic acid (KYNA)
might be a potential regulator of inflammatory processes in
arthritic joints (6). Moreover, in a recent study, it has been
observed that kynurenine prevents the development of the
disease, while inhibition or deletion of indoleamine 2, 3-
dioxygenase 1 (IDO1) has increased its severity (7).
Kynurenic acid is a product of the kynurenine pathway of
tryptophan metabolism (8). KYNA is an antagonist of ionotropic
glutamate receptors, such as N-methyl-D-aspartate (NMDA)
(9) and the α7 nicotinic acetylcholine receptor (α7nAchR)
(10, 11), and it exerts neuroprotective impacts (12, 13). In
addition, KYNA has a definitive immunomodulatory function
(14, 15) exerting anti-inflammatory and immunosuppressive
effects. These immunomodulatory properties are based on
the signaling by G-protein-coupled receptor 35 (GP35) and
aryl hydrocarbon receptor (ARH)-mediated pathways (16, 17).
Previously, it has been reported that the newly synthesized
analog of KYNA, such as 2-(2-N,N-dimethylaminoethylamine-1-
carbonyl)-1H-quinolin-4-one hydrochloride—SZR72 (Figure 1)
(18, 19) reduces TNF-α expression and secretion in human
monocytes (20). Likewise, the KYNA analog has been shown to
inhibit the secretion of α-defensin, such as HNP1–3 in human
granulocyte cultures (20).
The chemical attributes of KYNA and SZR-72 are different,
possibly influencing their ability to cross through the BBB (blood
Frontiers in Immunology | www.frontiersin.org 2 April 2021 | Volume 12 | Article 632513
Balog et al. Kynurenic Acid and Rheumatoid Arthritis
brain barrier) and membranes. There is evidence that KYNA
could only poorly cross the BBB, while SZR-72 is BBB-permeable
due to a water-soluble side chain with an extra cationic center
(9, 18, 21). Furthermore, a facilitated membrane crossing of SZR-
72 is suspected, which could influence intracellular signaling,
including the activation of antioxidative and anti-apoptotic
pathways (22). On the other hand, a distinct binding to the
glycine site of the NMDA receptor has a higher affinity to SZR72
than KYNA (22).
Considering all of the above, the aim of our present study
is to investigate the complex effects of a newly synthesized
KYNA analog—SZR72 on the in vitro production of TNF-α,
calprotectin (SA1008/9), SA100-12 [extracellular newly identified
receptor for advanced glycation end-products binding protein
(EN-RAGE)], and HNP1–3 (defensin-α) in the peripheral blood
of patients with RA. Previously, it has been proven that the
suppressive effect of the KYNA analog was more potent than that
of an equimolar concentration of KYNA itself (20); therefore,
this was used in the present study. These experiments were
supplemented bymeasuring the effect of the KYNA analog on the
tumor necrosis factor-stimulated gene-6 protein TSG-6 (TSG-6)
concentrations in the human blood samples, since an opposite
effect of KYNA on the TSG-6 production has formerly been
observed (23).
The role of TNF-α is widely characterized in the pathogenesis
of rheumatoid arthritis (RA) (4). Leukocyte activation and
infiltration are critical events in the pathogenesis of RA.
Relatedly, the role of calgranulins in the pathogenesis, diagnosis,
and monitoring of rheumatic diseases has gained great attention
FIGURE 2 | KYNA analog, SZR72 attenuates tumor necrosis factor-α (TNF-α)
production in whole blood cells of normal controls stimulated by
heat-inactivated Staphylococcus aureus. Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples of 1–1ml from each of 50 donors were
incubated with SZR72 at a concentration of 500µm for 30min prior to the
addition of heat-inactivated Staphylococcus aureus (107/ml). The
concentrations of TNF-α in the plasma were determined after 18 h-incubation
period. The data are depicted as box and whiskers plots, where the lines
inside the boxes denote medians, and the boxes mark the interval between 25
and 75 percentiles, and the whiskers, the maximum and minimum.
Significance was determined by the Friedman’s test followed by Dunn’s
post-test. In Friedman’d test, p < 0.0001; ooop < 0.001 in control vs. SA1,
###p < 0.001 in control vs. SA1 + SZR72, ***p < 0.001 in control vs. SA1.
in recent years (24, 25). Calgranulins are represented by the S100
protein family including S100A8, S100A9, and S100A12 (26). The
S100A8 and S100A9 complexes—as calprotectins—are found in
granulocytes and monocytes. S100A12 (EN-RAGE) is restricted
mainly to granulocytes (27, 28).
Human neutrophil peptide 1–3 (HNP1–3), also known as
defensin-α, may be secreted and released into the extracellular
milieu during an inflammatory response following the activation
of polymorphonuclear neutrophils during inflammation (29,
30). The defensin-α not only plays a role in microbial
killing, but also in immunomodulation during inflammatory
processes (31). The elevation of HNP1–3 has also been
reported in patients with RA (32, 33). Similarly, the so-
called calgranulins—calprotectin and S100A12 (EN-RAGE)—
correlated with the clinical status of patients with RA (24,
34). These data draw the attention to the role of these




Rheumatoid arthritis was classified according to the 2010
American College of Rheumatology (ACR)/European League
Against Rheumatism (EULAR) classification criteria for RA
(35). The detailed patient characteristics and clinical data are
presented in Table 1. Patients with RA (n = 93) were grouped
based on disease activity score in 28 joints (DAS28) of ≤2.6,
2.6 ≤ 3.2, 3.2 ≤ 5.1, and ≥5.1 remission (n = 30), mild (n
= 18), moderate (n = 27), and severe (n = 18), respectively.
Patients with RA were treated with biological response modifiers
as anti-TNF therapy (n = 29), IL-6R antagonist (n = 10),
rituximab (n = 4), abatacept (n = 1), tofacitinib (n = 1),
or with conventional disease-modifying antirheumatic drugs
(DMARDs), including methotrexate (n = 58), leflunomide
(n = 7), sulfosalazine (n = 3), chloroquine (n = 5), and
low dose methyl-prednisolone (n = 27). Anti-citrullinated
protein/peptide antibody (ACPA) was measured using the
ELISA-based routine laboratory methods with specificity to
mutated citrullinated vimentin (MCV). Patients with RA (n= 93)
were selected based on medication and their rheumatoid factor
status (RF), respectively.
As a further control group (healthy controls), we enrolled
50 age- and gender-matched healthy volunteers. All of them
had a negative history of RA symptoms and a negative
status upon detailed physical and laboratory examinations,
including normal CRP and ESR values. The project was
approved by the Ethics Committee of the University of
Szeged (ETT-TUKEB 905/PI/09 and 149/2019-SZOTE).
This study was conducted in full accordance with the
Declaration of Helsinki (1964). The patients/participants
provided their written informed consent to participate in
this study.
KYNA Analog SZR 72
KYNA amide (Figure 1) was designed in the Department of
Pharmaceutical Chemistry and MTA-SZTE Research Group for
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Stereochemistry, University of Szeged, Szeged, Hungary. The
synthesis was performed by the coupling of KYNA and 2-
dimethylaminoethylamine, afterwards, treatment of ethanolic
hydrogen chloride, resulting in N-(2-N, N-dimethylaminoethyl)-
4-oxo-1H-quinoline-2-carboxamide hydrochloride (18, 19, 21).
Human Blood Incubation Method
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated
peripheral blood samples from 93 patients with RA and 50
healthy controls were obtained. The samples (1ml each) were
incubated for 18 h in Heracell CO2 incubator (Thermo
Fischer Scientific, MA, USA) at 37◦C under controlled
conditions, or in the presence of heat-inactivated S. aureus
for 18 h (107/m) as a TNF inducer (36). Parallel blood
samples were pretreated before activation for 30min with
the KYNA analog at a concentration of 500µ. SZR72 was
freshly dissolved in phosphate buffered saline (PBS), thereafter
diluted in Roswell Park Memorial Institute (RPMI) medium
(SIGMA), and added in 100 µl volume to the blood sample.
All other samples were supplemented thereafter with 100 µl
RPMI medium to equalize the volumes. This concentration
of SZR72 was considered optimal for the experiments
performed previously (20, 23). Following the incubation
period, the blood samples were centrifuged at 3,000 g, and
the supernatants were tested for TNF-α (SIGMA, St. Louis,
USA), TSG-6 (Fine Biotech, Wuhan, China), calprotectin
(Hycult-Biotech, HK373-02, Uden, the Netherlands), S100A12
(CircuLex CY-8058 V2) (MBL International Corporation,
MA, USA), and HNP1–3 (Hycult-Biotech HK324, Uden, the
Netherlands) content by ELISA according to the instructions
of the manufacturers. For the experiments performed with
the human blood, we gained the approval of the ethics
committee of the Medical Faculty of the University of Szeged,
Szeged, Hungary (ETT-TUKEB 905/PI/09 and 149/2019
SZOTE). This study was conducted in full accordance with
the Declaration of Helsinki (1964). The patients/participants
provided their written informed consent to participate in
this study.
Statistics
Comparing different groups of patients and healthy controls,
the Kruskal–Wallis test was applied. For the comparison of the
FIGURE 3 | The effect of SZR72 on tumor necrosis factor-α (TNF-α) production in human whole blood cells of various groups of patients with RA stimulated by heat-
inactivated Staphylococcus aureus. Each dot represents the individual value for one subject, and the horizontal lines denote the medians. Significance was
determined by the Friedman’s test and Dunn’s post-test. Remission group: n = 30, p < 0.0001; control vs. SA1, significant, ooop < 0.001; control vs. SA1 + SZR72,
###p < 0.001; SA1 vs. SA1 + SZR72, ***p < 0.001 according to the Dunn’s post-test. Mild group: n = 18, p < 0.0001; control vs. SA1, ooop < 0.001; control vs.
SA1 + SZR72, non-significant; SA1 vs. SA1 + SZR72, **p < 0.01 according to the Dunn’s post-test. Moderate group: n = 27, p < 0.0001; control vs. SA1, ooop <
0.001; control vs. SA1 + SZR72, ##p < 0.01; SA1 vs. SA1 + SZR72, ***p < 0.001. Severe group: n = 18, control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72,
#p < 0.05; SA1 vs. SA1 + SZR72, **p < 0.01 according to the Dunn’s post-test.
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FIGURE 4 | The effect of KYNA analog, SZR72 on TSG-6 production in
human whole blood cells of normal donors stimulated by heat-inactivated
Staphylococcus aureus. Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples 1–1ml from each of 50 healthy donors
were incubated with SZR72 at a concentration of 500µm for 30min prior to
the addition of heat-inactivated Staphylococcus aureus (107/ml). The
concentrations of TSG-6 in the plasma were determined after an 18
h-incubation period. The data are depicted as box and whiskers plots, where
the lines inside the boxes denote medians, and the boxes mark the interval
between 25 and 75 percentiles, and the whiskers, the maximum and
minimum. Significance was determined by the Friedman’s test and Dunn’s
post-test. Control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ###p <
0.001; SA1 vs. SA1 + SZR72, ***p < 0.001.
concentrations of mediators within one group of patients, the
Friedman test was used with the Dunn’s post-test.
The p < 0.05 were considered significant. All statistical
calculations were performed with the Graph-Pad Prism 5
statistical program (Graph Pad Software Inc., San Diego,
CA, USA).
RESULTS
KYNA Analog, SZR72 Attenuates TNF-α
Production in the Human Whole Blood of
Healthy Controls and of Patients With RA
Stimulated by Heat-Inactivated
Staphylococcus aureus
In pilot experiments, we investigated the effect of SZR72 on
TNF-α production in healthy human blood donors (Figure 2).
During the course of these experiments, 500µm concentrations
of SZR72 were applied; hence in previous experiments, this
concentration proved to be the most effective (20, 23). There
was a significant decrease in the in vitro TNF-α concentration in
the supernatants of SA1-induced blood samples following SZR72
treatment. The TNF-α concentration in the basal (control) levels
of blood cultures was between 0.9 and 99.5 pg/ml with themedian
of 4.35 pg/ml, and in the supernatants, the SA1-induced blood
cultures were between 160 and 1,200 pg/ml, with a median of
450 pg/ml. SZR72 resulted in a significant decrease in TNF-α
concentration in SA1-induced blood samples to 200 ng/ml as a
median (Figure 2). Thereafter, we investigated to find whether
the TNF-α production and the effect of SZR72 on RA was
different in the various groups of the disease. Therefore, we
stratified the patients according to their clinical status, mild (n
= 18), moderate (n = 27), and severe (n = 18) status, or in
the remission phase (n = 30) of the disease. The inhibitory
effect of SZR72 on the SA1-mediated TNF-α production was
different in various groups of patients (Figure 3). The highest
concentrations were observed among patients with severe phase
of the disease (basal/control median level at 85 pg/ml; SA1-
induced median level at 995 pg/ml). The KYNA analog, SZR72
suppressed the TNF-α level of SA1-induced blood cultures to 500
pg/ml as a median; it was significant with the Friedman’s test and
with Dunn’s post-test (Figure 3). Similarly, SZR72 significantly
inhibited The SA1-induced TNF-α production in the remission
group, and also in the mild and moderate groups of patients
(Figure 3). The lowest basal/control TNF-α levels in the whole
blood supernatants were measured in the plasma samples of
patients with RA with the remission form of the disease [basal
level with a median of 5 pg/ml; SA1-induced concentration at a
median level of 30 pg/ml, and SZR72 suppressed it to 15 pg/m as
a median (Figure 3)].
The Effect of KYNA Analog SZR72 on
TSG-6 Production in Human Whole Blood
of Healthy Controls and of Patients With
RA Stimulated by Heat-Inactivated
Staphylococcus aureus
To ascertain whether the effects of the KYNA analog on the TNF-
α production might be influenced by the increased induction of
TSG-6, the concentrations of TSG-6 in whole blood cultures were
determined in 93 patients with RA comparing them with normal
control blood donors.
The TSG-6 level in the supernatants of basal/control
blood samples of healthy subjects were elevated following the
incubation with SA1, and it was further increased when 500
um SZR72 were added to the blood cultures (Figure 4). At a
concentration of 500µm, the KYNA analog SZR72 increased the
TSG-6 level significantly in SA1-induced blood samples, with the
median of 1,100 vs. 625 pg/ml, respectively, where p < 0.001
according to the Friedman’s test (Figure 4). These experiments
obtained with 500µm of KYNA analog support our previous
results (23) demonstrating the effects of KYNA and KYNA
analogs on the TSG-6 RNA expression and the elevation of TSG-6
protein level.
Next, we investigated to find whether the TSG-6 production
and the effect of SZR72 on it was different in the various groups of
the patients. Patients were categorized according to their clinical
status: mild (n = 18), moderate (n = 27), and severe (n = 18),
or being in the remission phase (n = 30) of the disease. The
TSG-6 production of the SA1-induced samples was increased
following SZR72 treatment in all groups of patients (Figure 5).
Interestingly but not surprisingly, the lowest concentrations
were observed in patients in the severe phase of the disease
(basal/control median level at 150 pg/ml; SA1-induced median
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FIGURE 5 | The effect of SZR72 on TSG-6 production in human whole blood cells of various groups of patients with RA stimulated by heat-inactivated
Staphylococcus aureus. Each dot represents the individual value for one subject, and the horizontal lines denote the medians. Significance was determined by the
Friedman’s test and Dunn’s post-test. Remission group: n = 30, p < 0.0001; control vs. SA1, non-significant; control vs. SA1 + SZR72, ###p < 0.001; SA1 vs. SA1
+ SZR72, ***p < 0.001 according to the Dunn’s post-test. Mild group: n = 18: p < 0.0001; control vs. SA1, non-significant; control vs. SA1 + SZR72, ###p <
0.001; SA1 vs. SA1 + SZR72, **p < 0.01. Moderate group: n = 27, control vs. SA1, non-significant; control vs. SA1 + SZR72, ###p < 0.001; SA1 vs. SA1 +
SZR72, ***p < 0.001. Severe group: n = 18: control vs. SA1, oop < 0.01; control vs. SA1 + SZR72, ###p < 0.001; SA1 vs. SA1 + SZR72, **p < 0.01.
level at 550 pg/ml). The KYNA analog, SZR72 increased the TSG-
6 level of SA1-induced blood cultures to 1,025 pg/ml as a median
(Figure 5). On the contrary, the highest basal TSG-6 levels in the
whole blood supernatants were measured in the plasma samples
of patients with RA in the remission form of the disease; the basal
level of TSG-6 showed amedian of 400 pg/ml, which was induced
to 1,800 pg/ml by SA1, and was further increased significantly
by 500µm SZR72 to 4,500 pg/ml (Figure 5). Similar results were
obtained by analyzing the patients in the mild phase of the
disease: basal level with a median of 445 pg/ml, SA1-induced
concentration at a median level of 550 pg/ml, and SZR72 were
increased to 4,950 pg/ml as a median.
The Effect of KYNA Analog, SZR72 on
Calprotectin Production in the Human
Whole Blood of Healthy Controls and of
Patients With RA Stimulated by
Heat-Inactivated Staphylococcus aureus
The role of calprotectin in the pathogenesis, diagnosis, and
monitoring of RA has gained great attention in recent years
(24, 25). Therefore, we investigated the effects of SZR 72 and
KYNA analog on the production of calprotectin in vitro in the
whole blood.
The concentrations in the basal levels of normal control
blood cultures were between 120 and 1,680 ng/ml with the
median of 500 ng/ml (Figure 6). The SA1-induced calprotectin
production in whole blood cultures is as follows: the calprotectin
concentrations in the supernatants in SA1-induced blood
cultures varied from 930 to 13,300 ng/ml, with a median of
1,900 ng/ml. At a concentration of 500µm, SZR72 suppressed
the calprotectin level significantly in the S. aureus-activated
blood cultures at a median of 1,000 ng/ml, where p < 0.01 with
Friedman’s test and Dunn’s post-test (Figure 6). We investigated
to find whether the calprotectin production and the effect of
SZR72 were different in the various groups of the disease.
Therefore, we grouped the patients according to their clinical
status as mild (n = 18), moderate (n = 26), and severe (n =
18), or being in remission phase (n = 33) of the disease. The
inhibitory effect of SZR72 on the SA1-mediated calprotectin
production was observed in all groups of patients, but at
a different level (Figure 7). As it was expected, the lowest
levels were detected in the blood samples of patients with RA
with a remission and mild state of the disease. Among the
remission group, the median was 911 ng/ml, which was induced
by SA1 (9,509 ng/mL) and SZR72 inhibited it to 6,520 ng/ml
as a median p < 0.001 according to the Friedman’s test.
Similar results were observed concerning the basal levels of
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FIGURE 6 | The effect of KYNA analog, SZR72 on calprotectin production in
human whole blood cells of normal donors stimulated by heat-inactivated
Staphylococcus aureus. Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples 1–1ml from each of 50 normal blood
donors were incubated with SZR72 at a concentration of 500µm for 30min
prior to the addition of heat-inactivated Staphylococcus aureus (107/ml). The
concentrations of calprotectin in the plasma were determined after an 18
h-incubation period. The data are depicted as box and whiskers plots, where
the lines inside the boxes denote medians, and the boxes mark the interval
between 25 and 75 percentiles, and the whiskers, the maximum and
minimum. Significance was determined by the Friedman’s test. Control vs.
SA1, ooop < 0.001; control vs. SA1 + SZR72, ###p < 0.001; SA1 vs. SA1
+ SZR72, ***p < 0.001, according to the Dunn’s post-test.
calprotectin among patients with the mild phase of the disease;
their basal level was measured as 680 ng/ml as median, which
was induced by SA1 to 7,000 ng/ml, and was decreased to
5,100 ng/ml as median following an incubation period of 18 h
with SZR 72 (Figure 7). In contrast, the basal/control median
level of calprotectin among patients with a severe status of
disease was 6,700 ng/ml, which was increased to 9,800 ng/ml
following the induction with SA1, and it was decreased to
800 ng/ml as a median as a result of treatment with 500µm
SZR72 (Figure 7). An intermediate basal level of calprotectin
in patients with moderate form of disease was found to be
at 1,050 ng/ml, and it was induced with Staphylococcus aureus
to 9,500 ng/ml, and was decreased to 5,770 ng/ml, respectively
(statistically significant according to the Friedman’s test and
Dunne’s post-test (Figure 7).
The Effect of the KYNA Analog, SZR72 on
S100A12 (EN-RAGE) Production in the
Human Whole Blood Cells of Normal
Controls and of Patients With RA
Stimulated by Heat-Inactivated
Staphylococcus aureus
As S100A12 (EN-RAGE) is the product of mainly granulocytes,
it may be of interest to investigate its level separately in
patients with RA, especially the effect of the KYNA analog
on the production of EN-RAGE by activated granulocytes in
whole blood cultures. The concentration of S100A12 (or EN-
RAGE) increased to 1,800 ng/ml in the basal levels of blood
cultures of control individuals were between 150 and 700 ng/ml
with the median of 250 ng/ml (Figure 8). SA1 induced the
EN-RAGE production in whole blood cultures as follows: the
EN-RAGE concentrations in the supernatants of SA1-induced
blood cultures varied between 950 and 4,500 ng/ml, with a
median of 1,800 ng/ml. At a concentration of 500µm, SZR72
suppressed the EN-RAGE level significantly in the S. aureus-
activated blood cultures at a median of 800 ng/ml, where p <
0.01 with Friedman’s test and Dunn’s post-test (Figure 8). We
investigated whether the EN-RAGE production and the effect of
SZR72 was different in the various groups of the disease. Patients
were categorized according to their clinical status as mild (n =
18), moderate (n = 27), or severe (n = 18) status, or being in
remission phase (n = 30) of the disease. The basal (control)
median of the EN-RAGE level in 30 samples of patients in the
remission phase was 1,500 ng/ml, which was elevated by SA1 up
to 7,100 ng/ml. SZR72 suppressed the SA1-induced EN-RAGE
production to 5,300 ng/ml, with the significance of ∗∗∗p < 0.001
(Figure 9). The basal median level of EN-RAGE in 18 samples
of the mild form of the disease was 1,215 ng/ml, which was
increased in SA1-induced samples with a median of 6,400 ng/ml.
SZR72 inhibited it to a median concentration of 3,750 ng/ml
(Figure 9). The median level of EN-RAGE in 27 samples of the
moderate group was 1,300 ng/ml, and that of the SA1-induced
samples was 8,400 ng/ml, and it was suppressed by SZR72 to
6,020 ng/ml, with the significance of ∗∗p < 0.01.
The EN-RAGE median level in 18 samples of patients with
severe status was the highest; from 2,500 ng/ml, it was increased
to 7,900 ng/ml by SA1, and decreased to 5,050 ng/ml by 500µm
SZR 72; where p < 0.01 according to the Friedman’s test and
Dunn’s post-test (Figure 9).
The Effect of the KYNA Analog, SZR72 on
HNP1–3 Production in the Human Whole
Blood Cells of Normal Controls and of
Patients With RA Stimulated by
Heat-Inactivated Staphylococcus aureus
Incubation of the whole blood of the healthy control of blood
donors with heat-inactivated S. aureus resulted in a significant
HNP-1 secretion. The median value of the basal level of HNP1–
3 was 106 ng/ml. An 18 h induction by Staphylococcus aureus
resulted in an increase in HNP1–3 level to 1,200 ng/ml. This
was inhibited by the pretreatment with 500 um SZR72 to a
median of 475 ng/ml (p < 0.001; Figure 10) for the comparison;
altogether, 89 blood samples of patients with RA were processed
for measuring HNP1–3 by ELISA.
We stratified the patients into different groups according to
their clinical status: 18 patients with the mild form of disease,
18 patients with the severe form of the disease, 25 patients with
the intermediate form of the disease, and 28 patients with the
remission phase of RA. The basal (control) median HNP1–3 level
in 28 samples of patients with the remission phase was 250 ng/ml,
which was elevated by SA1 up to 2,250 ng/ml. SZR72 suppressed
the SA1-induced EN-RAGE production to 1,000 ng/ml; however,
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FIGURE 7 | The effect of SZR72 on calprotectin production in human whole blood cells of various groups of patients with RA stimulated by heat-inactivated
Staphylococcus aureus. Each dot represents the individual value for one subject, and the horizontal lines denote the medians. Significance was determined by the
Friedman’s test. Remission group: n = 30, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR 72, ###p < 0.001; SA1 vs. SA1 + SZR72, ***p <
0.001 according to the Dunn’s post-test. Mild group: n = 18, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ##p < 0.01; SA1 vs. SA1 + SZR
72, *p < 0.05 according to the Dunn’s post-test. Moderate group: n = 27, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR 72, ##p < 0.001; SA1
vs. SA1 + SZR 72, **p < 0.01 according to the Dunn post’s test. Severe group: n = 18, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72,
non-significant; SA1 vs. SA1 + SZR72, ***p < 0.001 according to the Dunn’s post-test.
this was not statistically significant (Figure 11). The HNP1–
3 concentration varied from 100 to 240 ng/ml in the whole
blood samples of patients in the mild group (Figure 11). SA1
enhanced HNP1–3 secretion to 2,100 ng/ml as median, which
was suppressed to 900 ng/ml by SZR72 (p < 0.01, Figure 11).
When 25 samples from the moderate group were analyzed, the
median level of HNP1–3 was 280 ng/ml, and the increase in its
secretion was observed following SA1 induction to 1,500 ng/ml,
and SZR72 significantly (p < 0.001) reduced it to 600 ng/ml as
a median, which was also significant according to Friedman’s
test and Dunn’s post-test (Figure 11). The median basal level
of HNP1–3 in samples of patients having a severe form of the
disease was the highest, reaching 700 ng/ml. These high HNP1–3
levels might be the consequence of the degranulation of recruited
neutrophils. SA1 activation resulted in 2,550 ng/ml, and the
SZR72 treatment resulted in a decrease to 1,500 ng/ml, which was
statistically significant (p < 0.001, Figure 11).
Comparison of the Effect of SZR72 on the
Blood of Patients With RA Divided
According to Seropositivity and Medication
Both medication and RF status would influence on the
investigated parameters. Therefore, we compared the different
FIGURE 8 | The effect of KYNA analog, SZR72 on S100A12 (EN-RAGE)
production in human whole blood cells of normal blood donors stimulated by
heat-inactivated Staphylococcus aureus. Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples 1–1ml from each of 20 donors were
incubated with SZR72 at a concentration of 500µm for 30min prior to the
addition of heat-inactivated Staphylococcus aureus (107/ml). The
concentrations of EN-RAGE in the plasma were determined after an 18
h-incubation period. The data are depicted as box and whiskers plots, where
the lines inside the boxes denote medians, and the boxes mark the interval
between 25 and 75 percentiles, and the whiskers, the maximum and
minimum. Significance was determined by the Friedman’s test. Control vs.
SA1, ooop < 0.001; control vs. SA1 + SZR 72, ###p < 0.001; SA1 vs. SA1
+ SZR 72, ***p < 0.001, according to the Dunn’s post-test.
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FIGURE 9 | The effect of SZR72 on S100A12 (EN-RAGE) production in human whole blood cells of various groups of patients with RA stimulated by heat-inactivated
Staphylococcus aureus. Each dot represents the individual value for one subject, and the horizontal lines denote the medians. Significance was determined by the
Friedman’s test. Remission group: n = 30, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ###p < 0.001; ***SA1 vs. SA1 + SZR72,
p < 0.001 significant according to the Dunn’s post-test. Mild group: n = 18, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ###p < 0.001;
**SA1 vs. SA1 + SZR72, p < 0.01 significant with Dunn’s post-test, moderate group: n = 27, p < 0.0001, control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72,
###p < 0.001; SA1 vs. SA1 + SZR72, **p < 0.01, according to the Dunn’s post-test. Severe group: n = 18, p < 0.0001; control vs. SA1 ooop < 0.001, control vs.
SA1 + SZR72, #p < 0.05; SA1 vs. SA1 + SZR72, **p < 0.01 according to the Dunn’s post-test.
patient groups according to their medication (Figure 12). There
was no significant difference between the patients treated with
cDMARD (conventional) vs. bDMARD (biological therapy)
(Figure 12). Similarly, there was no different tendency in
response on the KYNA analog based on the RF status of the
patients (Figure 13).
CONCLUSION
This is the first complex study to investigate the effects of KYNA
analog, SZR72 on the in vitro production of TNF-α, TSG-6, and
the calgranulins as calprotectin and EN-RAGE, together with
HNP1–3 (defensin-α) in patients with RA in various activities of
the disease.
In the whole blood model, which resembles closely the
physiological milieu, the KYNA analog, SZR72 inhibited the
production not only of TNF-α, but also of calprotectin, EN-
RAGE, and HNP1–3 in the in vitro activated blood cultures of
patients with RA.
Granulocytic defensin-α secretion was measured in our
experiments also in whole blood cultures. Since granulocytes
are the main source of HNP1–3 in the peripheral blood, the
observations obtained from the investigation of whole blood
may be regarded as reflective of the granulocyte functions
(37, 38). Our previous experiments revealed that HNP1–3 was
FIGURE 10 | The effect of KYNA analog, SZR72 on HNP1–3 production in
human whole blood cells of normal blood donors stimulated by
heat-inactivated Staphylococcus aureus. Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples 1–1ml from each of 50 healthy donors
were incubated with SZR72 at a concentration of 500µm for 30min prior to
the addition of heat-inactivated Staphylococcus aureus (107/ml). The
concentrations of HNP-1 in the plasma were determined after an 18
h-incubation period. The data are depicted as box and whiskers plots, where
the lines inside the boxes denote medians, and the boxes mark the interval
between 25 and 75 percentiles, and the whiskers, the maximum and
minimum. Significance was determined by the Friedman’s test. The values,
ooop < 0.001 in control vs. SA1, ###p < 0.001 in control vs. SA1 + SZR72,
***p < 0.001 in SA1 + SZR72 vs. SA1.
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FIGURE 11 | The effect of SZR72 on HNP1–3 production in human whole blood cells of various groups of patients with RA stimulated by heat-inactivated
Staphylococcus aureus. Each dot represents the individual value for one subject, and the horizontal lines denote the medians. Significance was determined by the
Friedman’s test. Remission group: n = 28, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ###p < 0.001; SA1 vs. SA1 + SZR72,
non-significant, according to the Dunn’s post-test. Mild group: n = 18, p < 0.0001, control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, #p < 0.05, SA1 vs. SA1
+ SZR72, **p < 0.01 is significant with Dunn’s post-test; moderate group: n = 25, p < 0.0001; control vs. SA1, ooop < 0.001; control vs. SA1 + SZR72, ##p <
0.01; SA1 vs. SA1 + SZR72, ***p < 0.001 significant according to the Dunn’s post-test. Severe group: n = 18, p < 0.0001; ooop < 0.001; control vs. SA1, significant,
control vs. SA1 + SZR72, non-significant, ***SA1 vs. SA1 + SZR72, p < 0.001 significant according to the Dunn’s post-test.
secreted not only by purified granulocytes but also in the case
of the whole blood incubation method (20, 37). As mentioned,
neutrophil granulocytes are the main source of HNP1–3;
therefore, we suggest that the increase of HNP1–3 levels
following SA1 induction mostly originates from granulocyte
activity. Accordingly, we infer that the calgranulins in the
supernatants of whole blood cultures might be regarded as
products partially of monocytes and mainly of granulocytes (27,
28, 39).
There are previous data indicating the role of these
inflammatory mediators in the pathogenesis of RA. Especially,
TNF-α has a pivotal role in the exaggerated cytokine activation;
therefore, the therapeutic use of anti-TNF as a biological response
modifier has a pioneering importance in RA (4, 5). Higher levels
of calprotectin (24, 25, 40, 41), HNP1–3, and EN-RAGE in
sera of patients with RA have been detected in some clinical
studies (32–34).
In contrast, in our study, lower TSG-6 levels were detected
in the severe group of patients with RA compared to healthy
controls (Table 2). In the present study, the effect of the
KYNA analog was investigated on the TSG-6 production ex
vivo in human whole blood cultures of patients with RA. The
KYNA analog. SZR72 exerted a stimulatory effect on the TSG-
6 production in the whole blood cultures of patients with
RA in various activities of the disease. We hypothesize that
it contributes to the anti-inflammatory effect of the drug by
inhibiting the TNF-α synthesis (23, 42, 43). The beneficial role
of TSG-6 has been interpreted as inhibiting the association of
TLR4 with MyD88, thereby suppressing NF-κB activation (43).
TSG-6 has also prevented the expression of proinflammatory
proteins (iNOS, IL-6, TNFα, and IL-1β) (42), and its expression
might be under the influence of KYNA (44). Thus, we suppose
that increasing the production of TSG-6 by the KYNA analog
might contribute to the inhibitory effect toward TNF-α synthesis
in human blood cultures. The opposite effects of the KYNA
analogs on TNF-α and TSG-6 have been detected previously in
cell culture experiments (23).
In our experiments, SZR72 inhibited the production of the
inflammatory mediators in whole blood cultures, which were
induced by heat-inactivated SA1. This effect was observed in all
groups of patients in the various activities of the disease. It is
also noteworthy that the basic (control) levels of these mediators
were higher in the blood of patients than in healthy donors
(Table 2). When we compared the data of patients with that of
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FIGURE 12 | Levels of tumor necrosis factor-α (TNF-α), EN-RAGE, calprotectin, and TSG-6 at baseline and following treatments with SA1 and SA1 + SZR72 in
patients with RA on conventional disease modifying anti-rheumatic drugs (cDMARD, n = 41) or on biologic disease modifying anti-rheumatic drugs (bDMARD, n =
41). Comparisons were made with the Friedman’s test, where **p < 0.01 vs. control, ***p < 0.001 vs. control, and ###p < 0.001 vs. SA1. Horizontal line—median,
box—interquartile range, whiskers—range.
FIGURE 13 | Levels of TNF- α, EN-RAGE, calprotectin, and TSG-6 at baseline and following treatment with SA1 and SA1 + SZR72 in rheumatoid factor (RF) in
patients with positive (n = 72) and negative rheumatoid arthritis (RA) (n = 17). Comparisons were made with Friedman’s tests *p < 0.5 vs. control, ***p < 0.001 vs.
control, #p < 0.05 vs. SA1, ##p < 0.01 vs. SA1, ###p < 0.001 vs. SA1. Horizontal line—median, box—interquartile range, whiskers—range.
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n = 27 (25+)
RA active
n = 18
TNF-α pg/mL 4.35 [1.94–15] 5.0 [1.8–15.0] 6.5 [2.1–12.75] 15 [2.5–49.5] 85 [19.5–4,000]***
TSG-6 pg/mL 340 [237–510] 400 [307–500] 445 [257–537] 260 [200–310]* 150 [59–210]***
Calprotectin ng/mL 500 [220–712] 911 [648–1,420]*** 680 [345–861]ns 1,056 [560–6,390]** 6,700 [5,713–7,716]***
EN-RAGE ng/mL 250 [187–450] 1,300 [1,100–1,825]*** 1,215 [1,000–1,500]* 1,300 [1,190–1,800]*** 2,500 [2,400–5,800]***
HNP1–3 ng/mL (+) 106 [80–160] 250 [53–999]*** 143 [109–157]ns 280 [200–410]*** 700 [587–1,000]***
Data are expressed as median [interquartile range]. Comparisons were made using the Kruskal–Wallis test. ***p < 0.001 vs. healthy individuals, **p < 0.01 vs healthy individuals, *p <
0.05 vs healthy individuals, ns, non-significant, (+): 89 test of RA patients.
EN-RAGE, extracellular newly identified receptor for advanced glycation end-products binding protein; RA, rheumatoid arthritis; TNF-α, Tumor Necrosis Factor-α; TSG-6, Tumor Necrosis
Factor-Stimulated Gene-6.
healthy individuals (n = 50), the levels of TNF-α, calprotectin,
EN-RAGE, HNP1–3 were lower compared to the data of all
patients with RA. These data are in good correlation with the
observations, concluding that these inflammatory mediators are
higher in patients with RA (4, 5, 25, 32–34, 41). Inhibition
of their secretion can, therefore, additionally result in an anti-
inflammatory effect in RA.
In inflamed tissues, calprotectins (S100A8 and S100A9) have
a potential role as a target of treatment in murine models of
autoimmune disorders, since the direct or indirect blockade of
these proteins result in amelioration of the disease process (45).
In our experiments, the basal levels of these mediators were
further increased following the activation of the blood cells, but
the KYNA analog significantly reduced their production from the
activated cells.
It was of interest to observe whether normal (healthy) control
cells subjected to Staphylococcus antigen with or without SZR72
would react similarly or in a different way than cells from patients
with RA. Therefore, in a pilot study, we performed similar ex
vivo experiments with the 50 normal blood donors (Figures 2,
4, 6, 8, 10). On the basis of these results, we conclude that
SZR72 at 500µm exerted a significant inhibitory effect on TNF-
α, calprotectin, EN-RAGE, and HNP-1–3 production on SA1-
stimulated whole blood, and increased the TSG-6 production.
We compared the different patient groups according to their
medication (Figure 12). There was no significant difference
between the patients treated with cDMARD vs. bDMARD.
Similarly, there was no different tendency in response to the
KYNA analog based on RF status of the patients (Figure 13).
Our study has limitations. According to our previous results
(20, 23), 500µm of KYNA analog was used. The median level
of KYNA in human sera is at nanomolar (30–40 nm) range of
concentration (6, 46, 47). However, it increases considerably
in the course of infections and inflammatory processes due
to increased degradation of tryptophan. In addition, during
different in vitro experiments, micromolar concentrations were
found to be effective (44, 47). High micromolar concentrations
of KYNA are able to block NMDA receptor function (47).
Moreover, we have to take into consideration that in our study,
a potential therapeutic effect was investigated. Another question
is the duration of the incubation period of the whole blood, that
is, 18 h. For the determination of the effect of SA1 and the KYNA
analog on the cytokine-protein production, it was considered to
be necessary. Similarly, relatively long or even longer incubation
periods were applied in experiments with mice splenocytes (48),
or with human mesenchymal cells (44). In another study (6),
human mononuclear cells or human monocytes were treated
with KYNA at 0.5–1mm for 18 h for the determination of TNF-
α in cell culture supernatants following lipopolysaccharide (LPS)
induction. The potential degradation of SZR72 to KYNA in our
experiments was not investigated, but it cannot be excluded
(15, 49–51).
Taken together, these data further support the
immunomodulatory role of KYNA in RA (52), and may
draw the attention to the importance of the synthesis of the
KYNA analog, which might have a future therapeutic potential.
Therefore, we suggest that these experiments further explore the
potential benefits of the future application of the KYNA analogs
in RA.
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